Joseph Oliveto, Milestone Pharmaceuticals CEO
October 17, 2022 09:12 AM EDTUpdated 10:57 AM
R&D

Up­dat­ed: Mile­stone Phar­ma claims PhI­II re­demp­tion for its once-failed heart drug, putting it on a path to the FDA

John Carroll

Editor & Founder

More than two years af­ter Mile­stone Phar­ma­ceu­ti­cals’ stock got ham­mered af­ter their lead heart drug flopped in a cru­cial Phase III study, the biotech is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times